T
Tobias Schmelzle
Researcher at Novartis
Publications - 46
Citations - 6618
Tobias Schmelzle is an academic researcher from Novartis. The author has contributed to research in topics: Hippo signaling pathway & Transcription factor. The author has an hindex of 23, co-authored 41 publications receiving 5893 citations. Previous affiliations of Tobias Schmelzle include Harvard University & University of Basel.
Papers
More filters
Journal ArticleDOI
TOR, a Central Controller of Cell Growth
Tobias Schmelzle,Michael N. Hall +1 more
TL;DR: Findings reveal that the target of rapamycin TOR controls an unusually abundant and diverse set of readouts all of which are important for cell growth, suggesting that this conserved kinase is such a central regulator.
Journal ArticleDOI
Engineering tumors with 3D scaffolds.
Claudia Fischbach,Claudia Fischbach,Ruth R. Chen,Takuya Matsumoto,Tobias Schmelzle,Joan S. Brugge,Peter J. Polverini,David J. Mooney +7 more
TL;DR: This new biomimetic model may provide a broadly applicable 3D culture system to study the effect of microenvironmental conditions on tumor malignancy in vitro and in vivo.
Journal ArticleDOI
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald,Antoine de Weck,Michael R. Schlabach,Eric Billy,Konstantinos J. Mavrakis,Gregory R. Hoffman,Dhiren Belur,Deborah Castelletti,Elizabeth Frias,Kalyani Gampa,Javad Golji,Iris Kao,Li Li,Philippe Megel,Thomas A. Perkins,Nadire Ramadan,David A. Ruddy,Serena J. Silver,Sosathya Sovath,Mark Stump,Odile Weber,Roland Widmer,Jianjun Yu,Kristine Yu,Yingzi Yue,Dorothee Abramowski,Elizabeth Ackley,Rosemary Barrett,Joel Berger,Julie L. Bernard,Rebecca Billig,Saskia M. Brachmann,Frank Buxton,Roger Caothien,Justina X. Caushi,Franklin Chung,Marta Cortes-Cros,Rosalie deBeaumont,Clara Delaunay,Aurore Desplat,William Duong,Donald A. Dwoske,Richard S. Eldridge,Ali Farsidjani,Fei Feng,JiaJia Feng,Daisy Flemming,William C. Forrester,Giorgio G. Galli,Zhenhai Gao,François Gauter,Veronica Gibaja,Kristy Haas,Marc Hattenberger,Tami Hood,Kristen Hurov,Zainab Jagani,Mathias Jenal,Jennifer Johnson,Michael D. Jones,Avnish Kapoor,Joshua M. Korn,Jilin Liu,Qiumei Liu,Shumei Liu,Yue Liu,Alice T. Loo,Kaitlin J. Macchi,Typhaine Martin,Gregory McAllister,A. B. Meyer,Sandra Mollé,Raymond Pagliarini,Tanushree Phadke,Brian Repko,Tanja Schouwey,Frances Shanahan,Qiong Shen,Christelle Stamm,Christine Stephan,Volker M. Stucke,Ralph Tiedt,Malini Varadarajan,Kavitha Venkatesan,Alberto C. Vitari,Marco Wallroth,Jan Weiler,Jing Zhang,Craig Mickanin,Vic E. Myer,Jeffery A. Porter,Albert Lai,Hans Bitter,Emma Lees,Nicholas Keen,Audrey Kauffmann,Frank Stegmeier,Francesco Hofmann,Tobias Schmelzle,William R. Sellers +99 more
TL;DR: A large-scale RNAi screen is conducted in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.
Journal ArticleDOI
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Konstantinos J. Mavrakis,E. Robert McDonald,Michael R. Schlabach,Eric Billy,Gregory R. Hoffman,Antoine deWeck,David A. Ruddy,Kavitha Venkatesan,Jianjun Yu,Gregg McAllister,Mark Stump,Rosalie deBeaumont,Samuel B. Ho,Yingzi Yue,Yue Liu,Yan Yan-Neale,Guizhi Yang,Fallon Lin,Hong Yin,Hui Gao,D. Randal Kipp,Songping Zhao,Joshua T. McNamara,Elizabeth R. Sprague,Bing Zheng,Ying Lin,Young Shin Cho,Justin Gu,Kenneth Crawford,David N. Ciccone,Alberto C. Vitari,Albert Lai,Vladimir Capka,Kristen Hurov,Jeffery A. Porter,John A. Tallarico,Craig Mickanin,Emma Lees,Raymond Pagliarini,Nicholas Keen,Tobias Schmelzle,Francesco Hofmann,Frank Stegmeier,William R. Sellers +43 more
TL;DR: By interrogating data from a large-scale short hairpin RNA–mediated screen across 390 cancer cell line models, it is found that the viability of MTAP-deficient cancer cells is impaired by depletion of the protein arginine methyltransferase PRMT5.
Journal ArticleDOI
CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions
Diana M Munoz,Pamela J. Cassiani,Li Li,Eric Billy,Joshua M. Korn,Michael D. Jones,Javad Golji,David A. Ruddy,Kristine Yu,Gregory McAllister,Antoine deWeck,Dorothee Abramowski,Jessica Wan,Matthew D. Shirley,Sarah Y. Neshat,Daniel P. Rakiec,Rosalie de Beaumont,Odile Weber,Audrey Kauffmann,E. Robert McDonald,Nicholas Keen,Francesco Hofmann,William R. Sellers,Tobias Schmelzle,Frank Stegmeier,Michael R. Schlabach +25 more
TL;DR: It is shown that CRISPR-based screens have a significantly lower false-negative rate compared with RNAi- based screens, but have specific liabilities particularly in the interrogation of regions of genome amplification, therefore, this study provides critical insights for applying CRISpr-based screening toward the systematic identification of new cancer targets.